The primary aim of the present study was to further investigate the role of CYP2D6 for the outcome in a larger cohort of tamoxifen-treated early breast cancer, accounting for adherence to tamoxifen and exposure to potent CYP2D6 inhibitors. This evidence concerns the gene CYP2D6 and breast cancer.